These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 27011211)
1. Molecular Characterization of Clostridium difficile Isolates from Human Subjects and the Environment. Tian TT; Zhao JH; Yang J; Qiang CX; Li ZR; Chen J; Xu KY; Ciu QQ; Li RX PLoS One; 2016; 11(3):e0151964. PubMed ID: 27011211 [TBL] [Abstract][Full Text] [Related]
2. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14. Knight DR; Giglio S; Huntington PG; Korman TM; Kotsanas D; Moore CV; Paterson DL; Prendergast L; Huber CA; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV J Antimicrob Chemother; 2015 Nov; 70(11):2992-9. PubMed ID: 26221017 [TBL] [Abstract][Full Text] [Related]
3. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China. Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926 [TBL] [Abstract][Full Text] [Related]
4. Clostridium difficile isolated from faecal samples in patients with ulcerative colitis. Shoaei P; Shojaei H; Jalali M; Khorvash F; Hosseini SM; Ataei B; Vakili B; Ebrahimi F; Tavakoli H; Esfandiari Z; Weese JS BMC Infect Dis; 2019 Apr; 19(1):361. PubMed ID: 31039738 [TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from the Chinese People's Liberation Army General Hospital in China. Wang R; Suo L; Chen HX; Song LJ; Shen YY; Luo YP Int J Infect Dis; 2018 Feb; 67():86-91. PubMed ID: 28736259 [TBL] [Abstract][Full Text] [Related]
6. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166 [TBL] [Abstract][Full Text] [Related]
8. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Huang H; Fang H; Weintraub A; Nord CE Clin Microbiol Infect; 2009 Dec; 15(12):1170-3. PubMed ID: 19624517 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ; J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology of Clostridium difficile infection in hospitalized adults and the first isolation of C. difficile PCR ribotype 027 in central China. Zhou Y; Mao L; Yu J; Lin Q; Luo Y; Zhu X; Sun Z BMC Infect Dis; 2019 Mar; 19(1):232. PubMed ID: 30845918 [TBL] [Abstract][Full Text] [Related]
11. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Huang H; Wu S; Wang M; Zhang Y; Fang H; Palmgren AC; Weintraub A; Nord CE Int J Antimicrob Agents; 2009 Apr; 33(4):339-42. PubMed ID: 19097757 [TBL] [Abstract][Full Text] [Related]
12. A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea. Byun JH; Kim H; Kim JL; Kim D; Jeong SH; Shin JH; Kim YA; Shin JH; Shin KS; Uh Y Anaerobe; 2019 Dec; 60():102106. PubMed ID: 31655214 [TBL] [Abstract][Full Text] [Related]
13. Clostridium difficile ribotype 176 - A predictor for high mortality and risk of nosocomial spread? Polivkova S; Krutova M; Petrlova K; Benes J; Nyc O Anaerobe; 2016 Aug; 40():35-40. PubMed ID: 27155489 [TBL] [Abstract][Full Text] [Related]
14. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran. Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133 [TBL] [Abstract][Full Text] [Related]
15. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from a university teaching hospital in Japan. Kuwata Y; Tanimoto S; Sawabe E; Shima M; Takahashi Y; Ushizawa H; Fujie T; Koike R; Tojo N; Kubota T; Saito R Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):763-72. PubMed ID: 25471195 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Huang H; Weintraub A; Fang H; Wu S; Zhang Y; Nord CE Anaerobe; 2010 Dec; 16(6):633-5. PubMed ID: 20849968 [TBL] [Abstract][Full Text] [Related]
17. The epidemiology of Clostridium difficile in Scotland. Wiuff C; Brown DJ; Mather H; Banks AL; Eastaway A; Coia JE J Infect; 2011 Apr; 62(4):271-9. PubMed ID: 21300104 [TBL] [Abstract][Full Text] [Related]
18. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin. Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985 [TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of community-onset Clostridioides difficile infections at a tertiary hospital in mainland China: A fourteen-year (2010-2023) retrospective study. Jiang X; Bian J; Lv T; Zheng L; Zhao Y; He J; Chen Y Int J Med Microbiol; 2024 Sep; 316():151631. PubMed ID: 39024723 [TBL] [Abstract][Full Text] [Related]
20. Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait. Jamal WY; Rotimi VO PLoS One; 2016; 11(8):e0161411. PubMed ID: 27536994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]